LLY launches a discounted version of Zepbound. European Commission approves JNJ's Balversa, MRK's Winrevair and RHHBY's PiaSky.
Vous n'êtes pas connecté
Eli Lilly (LLY), Novo Nordisk (NVO) and Bayer (BAYRY) announce second-quarter results. Merck (MRK) expands existing co-development deal with partner Daiichi Sankyo.
LLY launches a discounted version of Zepbound. European Commission approves JNJ's Balversa, MRK's Winrevair and RHHBY's PiaSky.
European Commission approves expanded use of Merck's Keytruda in bladder cancer. Sanofi & Lilly announce data from phase III studies on pipeline...
Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
JWN's second-quarter earnings results benefit from Anniversary Sale timing, which led to the shift of one week from the third quarter to the second...
DLTR posts soft second-quarter fiscal 2024 results due to a challenging macro backdrop.
DLTR posts soft second-quarter fiscal 2024 results due to a challenging macro backdrop.
DKS posts robust second-quarter fiscal 2024 results, thanks to the solid execution of its strategic efforts.